The S&P 500 has had a volatile start to 2025 but has still managed to gain 3.8% year to date as of market close on Jan. 24.
It was about a year ago that shares of Iovance Biotherapeutics ( IOVA -1.94%) began to take off. The stock soared on news of approval from the Food and Drug Administration for Amtagvi (lifileucel) as ...
If you want to get the most out of your 401 (k) account, you obviously need to contribute money of your own. But you also ...
Buybacks continue to progress, and GM met its goal of fewer than 1 billion outstanding shares at the end of 2024. Plus, the company is improving its balance sheet, paying off $750 million in debt ...
Dan Ives leads technology research at Wedbush Securities and has long been an Nvidia bull. Despite the news out of DeepSeek, Ives remains incredibly optimistic about Nvidia's future and just called ...
Looking ahead to fiscal 2025, Tractor Supply is targeting net sales growth in the mid-single digits, with an EPS range ...
Like all companies, American Express' fortunes wax and wane over time. But if you think in decades and not days, it is a very ...
Palantir would need to grow into a $6.7 trillion market cap to turn a $25,000 investment into $1 million. This would be its ...
The transformative power of artificial intelligence (AI) is undeniable. A recent McKinsey & Company research report estimates ...
Buffett's largest holding at Berkshire is counting on artificial intelligence (AI) to reignite its growth engine. Meanwhile, ...
In a nutshell, Innovative Industrial Properties' stock is way down because the REIT's largest tenant, PharmaCann, has fallen ...
With growth coming in hot, Axon Enterprise's shareholders enjoyed a great year. In 2024, Axon stock jumped 130%, skyrocketing ...